ReviewFrontiers in microbiology2013
From antimicrobial to anticancer peptides. A review.
Review in Frontiers in microbiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 308 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
308 citing papers in PubMed, 728 citations in OpenAlex.
- LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma.Oncoimmunology · 2024Trial
- Enhanced anticancer efficacy ofMaterials today. Bio · 2026Article
- Microbe-Derived Antimicrobial Peptides: Immunomodulation and Gut Microbiota Homeostasis.Microorganisms · 2026Review
- Synthesis and Fundamental Evaluation of [ACS omega · 2026Article
- Marine Antimicrobial Peptides: From Ocean Biodiversity to Genome Mining, Multi-Omics Discovery, and Biotechnological Innovation in the Battle Against Antimicrobial Resistance.Probiotics and antimicrobial proteins · 2026Review
- Anticancer effects of alpha-helical peptide epinecidin-1 and its variants in combination with doxorubicin.Medical oncology (Northwood, London, England) · 2026Article
- Engineering the Host Defense Peptide from Scorpion Venom for Safer and More Potent Antibreast Cancer Activity.ACS pharmacology & translational science · 2026Article
- From Innate Immunity to Cancer Therapy: Antimicrobial Peptides as Emerging Anticancer Agents.International journal of molecular sciences · 2026Review
- Dual Activity Microbial Peptides Catalog.Scientific data · 2026Article
- Antimelanoma Activity of the Mastoparan Peptides MPX and MP1: Cellular Selectivity and Mechanism of Action.Molecular pharmaceutics · 2026Article
- Cancer Susceptibility to Stapled Oncolytic Peptides Is Dictated by Membrane Cholesterol and Inflammatory Signaling.Cancer research · 2026Article
- Streptococcus-derived CpsA-CpsC fusion protein induces apoptosis in cervical cancer cells through in silico and in vitro methods.Scientific reports · 2026Article
- Aggregation-State Dynamics Drive Double Cooperativity Between Antimicrobial Peptides LL-37 and HNP1.Angewandte Chemie (International ed. in English) · 2026Article
- MAPLE: interpretable deep learning identifies selective antimicrobial peptides using joint evolutionary-physicochemical analysis.Briefings in bioinformatics · 2026Article
- Anticancer Activity of the Antimicrobial Myristoylated Peptide Myr-B in HeLa Cells: Cytotoxic, Membrane-Disruptive and Proteomic Insights.International journal of molecular sciences · 2026Article
- ACP-EPC: an interpretable deep learning framework for anticancer peptide prediction utilizing pre-trained protein language model and multi-view feature extracting strategy.Molecular diversity · 2026Article
- Enhancing anticancer peptide discovery: A fusion-centric framework with conditional diffusion for prediction and generation.PLoS computational biology · 2026Article
- Pep5-Cpp, a Cyclin D2-Derived Antimicrobial.Molecules (Basel, Switzerland) · 2026Article
- Liposomal Encapsulation Reduces the Cytotoxic Effects of Gramicidin S in Monolayer and Spheroid Fibroblast Cultures.Antibiotics (Basel, Switzerland) · 2026Article
- Truncated Equinin B Variants Reveal the Sequence Determinants of Antimicrobial Selectivity.Marine drugs · 2026Article
248 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial peptides (AMPs) are part of the innate immune defense mechanism of many organisms. Although AMPs have been essentially studied and developed as potential alternatives for fighting infectious diseases, their use as anticancer peptides (ACPs) in cancer therapy either alone or in combination with other conventional drugs has been regarded as a therapeutic strategy to explore. As human cancer remains a cause of high morbidity and mortality worldwide, an urgent need of new, selective, and more efficient drugs is evident. Even though ACPs are expected to be selective toward tumor cells without impairing the normal body physiological functions, the development of a selective ACP has been a challenge. It is not yet possible to predict antitumor activity based on ACPs structures. ACPs are unique molecules when compared to the actual chemotherapeutic arsenal available for cancer treatment and display a variety of modes of action which in some types of cancer seem to co-exist. Regardless the debate surrounding the definition of structure-activity relationships for ACPs, great effort has been invested in ACP design and the challenge of improving effective killing of tumor cells remains. As detailed studies on ACPs mechanisms of action are crucial for optimizing drug development, in this review we provide an overview of the literature concerning peptides' structure, modes of action, selectivity, and efficacy and also summarize some of the many ACPs studied and/or developed for targeting different solid and hematologic malignancies with special emphasis on the first group. Strategies described for drug development and for increasing peptide selectivity toward specific cells while reducing toxicity are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.